BRCA1 and familial pancreatic carcinoma: In the past decades, studies have found that these unique vulnerabilities inherent in BRCA1/2 mutant cancers (e.g., breast, ovarian, and pancreatic cancers) could be utilized to induce synthetic lethality [7].